Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of Intraperitoneal Bevacizumab for Malignant Ascites
NCT02496286Phase 1Terminated
- Sponsor
- City of Hope Philadelphia
- Start
- Jun 2015
- Primary completion
- Aug 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bevacizumab in malignant ascites, sponsored by City of Hope Philadelphia. Primary endpoints: Radiographic Improvement at 14 days, Volume Output at 14 days and 1 more. Started Jun 2015; status: terminated.
02
Drugs
bevacizumab
03
Conditions
malignant ascites
Beyond the preview
Go deeper on NCT02496286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02496286.